Abstract Number: 2738 • 2018 ACR/ARHP Annual Meeting
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPeter A. Merkel1, David…Abstract Number: 2739 • 2018 ACR/ARHP Annual Meeting
Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
Background/Purpose: The glucocorticoid toxicity index (GTI) (Miloslavsky et al. Ann Rheum Dis 2017) is useful to assess impact on morbility associated with these drugs. It…Abstract Number: 2740 • 2018 ACR/ARHP Annual Meeting
Clinical and Laboratory Characteristics of ANCA-Associated Vasculitis in Pediatric and Young Adult Patients: A Retrospective Review
Background/Purpose: ANCA-associated vasculitis (AAV) is a heterogenous group of small-vessel vasculitides that typically affects the kidneys, respiratory tract, and other organ systems. The onset of…Abstract Number: 2741 • 2018 ACR/ARHP Annual Meeting
Candidate Biomarkers in ANCA-Associated Vasculitis Identified Using a Proteomic Approach
Background/Purpose: Concentrations of many circulating proteins are elevated during severe, active ANCA-associated vasculitis (AAV). Finding biomarkers associated with milder disease, a more clinically relevant need,…Abstract Number: 2742 • 2018 ACR/ARHP Annual Meeting
Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study
Background/Purpose: Vasculitic neuropathy (VN) is a major complication of systemic vasculitis and contributes to morbidity, functional limitation, and health care utilization in affected patients. Patient…Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting
Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation
Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…Abstract Number: 2744 • 2018 ACR/ARHP Annual Meeting
Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study
Background/Purpose: Giant-cell arteritis (GCA) is the most common primary large-vessel vasculitis affecting patients over 50 yr. Despite frequent and severe adverse events (AEs), glucocorticoids (GCs)…Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting
Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents
Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study
Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…Abstract Number: 2747 • 2018 ACR/ARHP Annual Meeting
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy…Abstract Number: 2748 • 2018 ACR/ARHP Annual Meeting
Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis which can involve the aorta and/or its major branches. Tocilizumab (TCZ) seems to be effective in…Abstract Number: 2749 • 2018 ACR/ARHP Annual Meeting
Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by pain and stiffness of the neck, shoulder and pelvic girdles. It can also be accompanied…Abstract Number: 2750 • 2018 ACR/ARHP Annual Meeting
Utility of Methotrexate in Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is a frequent inflammatory condition in patients over 50 years old. Nearly 60% of patients experience relapses of the symptoms during…Abstract Number: 2751 • 2018 ACR/ARHP Annual Meeting
Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial
Background/Purpose: Adding tocilizumab (TCZ) to tapered prednisone treatment for patients (pts) with giant cell arteritis (GCA) leads to improved rates of sustained glucocorticoid-free remission.1 It…Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…
ACR Meeting Abstracts